The Complaint, alleges that Janssen failed to properly warn patients and their physicians about the substantial vision risks associated with use of their drug Elmiron. The complaint further states, "According to the [email protected] website, the label for Elmiron has been updated on approximately five occasions, at no time has it contained any information about vision loss, including pigmentary maculopathy, in any section of the label. The only mention in the label of any visual adverse events is a disclosure in the Adverse Reactions section that reveals clinical trial patients reported conjunctivitis, optic neuritis, amblyopia, and retinal hemorrhage. However, none of these adverse events are related to pigmentary maculopathy." The cases, English v. Janssen Pharmaceuticals, Inc. et al.andPisco v. Janssen Pharmaceuticals, Inc. et al., were filed in the United States District Court for the Eastern District of Pennsylvania on May 6, 2020.
Janssen Pharmaceuticals, part of the Johnson & Johnson umbrella of companies, is a Pennsylvania corporation. These companies have marketed Elmiron since the 2000s. The Plaintiff alleges that the company has never provided any warning of maculopathy or retinopathy associated with use of the drug or warned patients to have regular eye exams to monitor vision while using the drug.
Timothy J. Becker and Stacy K Hauer of Johnson // Becker are counsel of record. Mr. Becker and Ms. Hauer have a combined experience of more than 40 years of litigating mass tort cases involving pharmaceuticals and medical devices.
Talk to Your Doctor About Elmiron Associated Retinal Maculopathy
If you or a loved one has ever taken Elmiron, you should have your eyes examined by an Opthamologist. Download our free PDF guide that you can share with your primary care provider, urologist or ophthalmologist that provides valuable information on the latest research and discoveries pertaining to Elmiron associated retinal maculopathy.